IBM Watson for Drug Discovery helps researchers identify novel drug targets and new indications for existing drugs.
Barrow began working with IBM to explore unidentified genes and proteins that may be linked to ALS using its life sciences solution, Watson for Drug Discovery.
In collaboration with the Barrow Neurological Institute, Dr. Robert Bowser and his team of researchers used Watson for Drug Discovery to help identify new targets for ALS research.
By partnering with IBM’s Watson for Drug Discovery, Pfizer hopes to more quickly analyze and test hypotheses from “massive volumes of disparate data sources”.
Pfizer is one of the first organizations worldwide to deploy Watson for Drug Discovery – tapping in to Watson’s machine learning, natural language processing, and other cognitive reasoning technologies.